Clinical Experience with URO17® in the Diagnosis and Surveillance of Bladder Cancer

<b>Objective:</b> To describe the clinical use of URO17^®, a noninvasive, urine-based immunocytochemistry assay targeting Keratin 17 (K17), as an adjunct to conventional diagnostic methods for urothelial carcinoma. <b>Materials and Methods:</b> These illustrative cases summarize the real-world use of URO17^® in diagnostic workflows for patients presenting with hematuria and those undergoing surveillance for non-muscle invasive bladder cancer (NMIBC). Urine samples were processed via standard immunocytochemistry and interpreted alongside cystoscopic, cytological, and radiographic findings. <b>Discussion:</b> URO17^® was used as a complementary diagnostic tool to help guide clinical management. Negative results supported deferral of invasive procedures in selected patients, while positive findings prompted further evaluation when standard tests were inconclusive. <b>Conclusions:</b> In the seven illustrative cases presented, URO17^® aided clinical decision-making as part of routine diagnostic and surveillance workflows. The test's integration with existing cytology processes supports its potential role as a noninvasive adjunct for evaluating patients with suspected or recurrent urothelial carcinoma.